Atara Biotherapeutics (ATRA) Competitors

Atara Biotherapeutics (NASDAQ:ATRA) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, community ranking, analyst recommendations, earnings and valuation.

Is ATRA or ALVR more profitable?

AlloVir has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -132.58%. Atara Biotherapeutics' return on equity of 0.00% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-132.58%	N/A	-90.16%
AlloVir	N/A	-71.03%	-61.27%

Which has preferable valuation and earnings, ATRA or ALVR?

AlloVir has lower revenue, but higher earnings than Atara Biotherapeutics. AlloVir is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$8.57M	8.07	-$276.13M	-$25.78	-0.47
AlloVir	N/A	N/A	-$190.42M	-$0.88	-0.65

Do institutionals & insiders have more ownership in ATRA or ALVR?

70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 3.7% of Atara Biotherapeutics shares are held by insiders. Comparatively, 33.9% of AlloVir shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has more volatility and risk, ATRA or ALVR?

Atara Biotherapeutics has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.

Does the media prefer ATRA or ALVR?

In the previous week, Atara Biotherapeutics had 2 more articles in the media than AlloVir. MarketBeat recorded 8 mentions for Atara Biotherapeutics and 6 mentions for AlloVir. AlloVir's average media sentiment score of 0.87 beat Atara Biotherapeutics' score of 0.60 indicating that AlloVir is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atara Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AlloVir	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend ATRA or ALVR?

Atara Biotherapeutics currently has a consensus price target of $16.67, suggesting a potential upside of 38.89%. Given Atara Biotherapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Atara Biotherapeutics is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
AlloVir	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

Does the MarketBeat Community favor ATRA or ALVR?

Atara Biotherapeutics received 405 more outperform votes than AlloVir when rated by MarketBeat users. Likewise, 67.39% of users gave Atara Biotherapeutics an outperform vote while only 57.45% of users gave AlloVir an outperform vote.

Company	Underperform	Outperform
Atara Biotherapeutics	Outperform Votes 432 67.39%	Underperform Votes 209 32.61%
AlloVir	Outperform Votes 27 57.45%	Underperform Votes 20 42.55%

Summary

Atara Biotherapeutics beats AlloVir on 10 of the 17 factors compared between the two stocks.